LTR Pharma Signs Partnership on Intranasal Spray Development for Esophageal Motility Disorders

MT Newswires Live

2025/05/08

LTR Pharma (ASX:LTP) agreed to collaborate with Strategic Drug Solutions to co-develop Oroflow, a novel intranasal spray targeting esophageal motility disorders, according to a Thursday filing with the Australian bourse.

Esophageal motility disorders are conditions that disrupt the normal movement of food and liquids down the esophagus, leading to swallowing difficulties and impacting quality of life, the filing said.

The program is set to begin proof-of-concept testing in the coming months, according to the filing.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2533615918"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533615918\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533615918?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-08 09:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533615918","market":"nz","top_or_hot":-1,"title":"LTR Pharma Signs Partnership on Intranasal Spray Development for Esophageal Motility Disorders","media":"MT Newswires Live","content":"<html><body><p> LTR Pharma (ASX:LTP) agreed to collaborate with Strategic Drug Solutions to co-develop Oroflow, a novel intranasal spray targeting esophageal motility disorders, according to a Thursday filing with the Australian bourse.</p><p>Esophageal motility disorders are conditions that disrupt the normal movement of food and liquids down the esophagus, leading to swallowing difficulties and impacting quality of life, the filing said.</p><p>The program is set to begin proof-of-concept testing in the coming months, according to the filing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LTR Pharma Signs Partnership on Intranasal Spray Development for Esophageal Motility Disorders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLTR Pharma Signs Partnership on Intranasal Spray Development for Esophageal Motility Disorders\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-08 09:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> LTR Pharma (ASX:LTP) agreed to collaborate with Strategic Drug Solutions to co-develop Oroflow, a novel intranasal spray targeting esophageal motility disorders, according to a Thursday filing with the Australian bourse.</p><p>Esophageal motility disorders are conditions that disrupt the normal movement of food and liquids down the esophagus, leading to swallowing difficulties and impacting quality of life, the filing said.</p><p>The program is set to begin proof-of-concept testing in the coming months, according to the filing.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2533615918","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533615918","pubTimestamp":1746666596,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"LTR Pharma  agreed to collaborate with Strategic Drug Solutions to co-develop Oroflow, a novel intranasal spray targeting esophageal motility disorders, according to a Thursday filing with the Australian bourse.Esophageal motility disorders are conditions that disrupt the normal movement of food and liquids down the esophagus, leading to swallowing difficulties and impacting quality of life, the filing said.The program is set to begin proof-of-concept testing in the coming months, according to the filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","LTP.AU":"LTR PHARMA LTD"},"translate_title":"LTR Pharma签署合作伙伴关系，开发治疗食管动力障碍的鼻内喷雾剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LTP.AU":0.9},"content_text":"LTR Pharma (ASX:LTP) agreed to collaborate with Strategic Drug Solutions to co-develop Oroflow, a novel intranasal spray targeting esophageal motility disorders, according to a Thursday filing with the Australian bourse.Esophageal motility disorders are conditions that disrupt the normal movement of food and liquids down the esophagus, leading to swallowing difficulties and impacting quality of life, the filing said.The program is set to begin proof-of-concept testing in the coming months, according to the filing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}